Literature DB >> 8417885

A three-year study of severe community-acquired pneumonia with emphasis on outcome.

J Rello1, E Quintana, V Ausina, A Net, G Prats.   

Abstract

Fifty-eight consecutive patients with severe community-acquired pneumonia were studied prospectively during a three-year period. The group included 44 men and 14 women (mean age: 45.0 +/- 15.7 years). The cause of pneumonia was diagnosed in 35 (60.3 percent) cases, and the most common pathogens were Streptococcus pneumoniae (37.1 percent), Legionella pneumophila (22.8 percent) and Gram-negative bacilli (11.4 percent). The fact that Mycobacterium tuberculosis was present in four (11.4 percent) patients and Pneumocystis carinii in three (8.5 percent) is worthy of note. The overall death rate was 22.4 percent. More than 50 percent of deaths occurred within the first five days and were caused by septic shock, hemoptysis (tuberculosis) or hypoxia. However, hypoxia remains the main fatal complication and all late-occurring deaths (> 5 days) observed were due to this cause. These data could be important in planning strategies and protocols to improve prognosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8417885     DOI: 10.1378/chest.103.1.232

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  24 in total

1.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

2.  Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia.

Authors:  J A Brandenburg; T J Marrie; C M Coley; D E Singer; D S Obrosky; W N Kapoor; M J Fine
Journal:  J Gen Intern Med       Date:  2000-09       Impact factor: 5.128

3.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

4.  Acute pneumonia and systemic lupus erythematosus.

Authors:  M V Sun; P J Kaplan
Journal:  Proc (Bayl Univ Med Cent)       Date:  2001-01

5.  Distinctive features between community-acquired pneumonia (CAP) due to Chlamydophila psittaci and CAP due to Legionella pneumophila admitted to the intensive care unit (ICU).

Authors:  A Gacouin; M Revest; J Letheulle; P Fillatre; S Jouneau; C Piau; F Uhel; P Tattevin; Y Le Tulzo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-04-28       Impact factor: 3.267

6.  Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society.

Authors:  L A Mandell; T J Marrie; R F Grossman; A W Chow; R H Hyland
Journal:  Can J Infect Dis       Date:  2000-09

7.  Prospective study of epidemiology and prognostic factors in community-acquired pneumonia.

Authors:  J Gómez; V Baños; J Ruiz Gómez; M C Soto; L Muñoz; M L Nuñez; M Canteras; M Valdés
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-07       Impact factor: 3.267

Review 8.  Prognosis factors in severe community-acquired pneumonia: a step forward.

Authors:  A Torres; M el-Ebiary
Journal:  Intensive Care Med       Date:  1996-12       Impact factor: 17.440

Review 9.  The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis.

Authors:  M H Rozenbaum; P Pechlivanoglou; T S van der Werf; J R Lo-Ten-Foe; M J Postma; E Hak
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-12-14       Impact factor: 3.267

10.  Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns.

Authors:  Wen-Chien Ko; David L Paterson; Anthanasia J Sagnimeni; Dennis S Hansen; Anne Von Gottberg; Sunita Mohapatra; Jose Maria Casellas; Herman Goossens; Lutfiye Mulazimoglu; Gordon Trenholme; Keith P Klugman; Joseph G McCormack; Victor L Yu
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.